Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maryka Quik

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Trends in Neurosciences|August 28, 2004
Smoking, nicotine and Parkinson's diseaseMaryka Quik
Pharmacological Reviews|October 5, 2011
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's diseaseMaryka Quik, Susan Wonnacott
Molecular and Cellular Pharmacology|April 19, 2011
Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease TherapeuticsXiomara A Pérez, Maryka Quik
Neurotoxicology|November 14, 2002
Nicotine and nicotinic receptors; relevance to Parkinson's diseaseMaryka Quik, Jennifer M Kulak
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2005
Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapyMaryka Quik, J Michael McIntosh
Biochemical Pharmacology|July 17, 2007
Nicotinic receptors as CNS targets for Parkinson's diseaseMaryka Quik, Tanuja Bordia, Kathryn O'Leary
Movement Disorders : Official Journal of the Movement Disorder Society|June 14, 2012
Nicotine as a potential neuroprotective agent for Parkinson's diseaseMaryka Quik, Xiomara A Perez, Tanuja Bordia
Movement Disorders : Official Journal of the Movement Disorder Society|August 7, 2008
Nicotine and Parkinson's disease: implications for therapyMaryka Quik, Kathryn O'Leary, Caroline M Tanner
Neurotoxicology|March 25, 2008
Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cellsKaren Riveles, Luping Z Huang, Maryka Quik
Biochemical Pharmacology|July 9, 2013
Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout miceMaryka Quik, Carla Campos, Sharon R Grady
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Trends in Neurosciences|August 28, 2004
Smoking, nicotine and Parkinson's diseaseMaryka Quik
Pharmacological Reviews|October 5, 2011
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's diseaseMaryka Quik, Susan Wonnacott
Molecular and Cellular Pharmacology|April 19, 2011
Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease TherapeuticsXiomara A Pérez, Maryka Quik
Neurotoxicology|November 14, 2002
Nicotine and nicotinic receptors; relevance to Parkinson's diseaseMaryka Quik, Jennifer M Kulak
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2005
Striatal alpha6* nicotinic acetylcholine receptors: potential targets for Parkinson's disease therapyMaryka Quik, J Michael McIntosh
Biochemical Pharmacology|July 17, 2007
Nicotinic receptors as CNS targets for Parkinson's diseaseMaryka Quik, Tanuja Bordia, Kathryn O'Leary
Movement Disorders : Official Journal of the Movement Disorder Society|June 14, 2012
Nicotine as a potential neuroprotective agent for Parkinson's diseaseMaryka Quik, Xiomara A Perez, Tanuja Bordia
Movement Disorders : Official Journal of the Movement Disorder Society|August 7, 2008
Nicotine and Parkinson's disease: implications for therapyMaryka Quik, Kathryn O'Leary, Caroline M Tanner
Neurotoxicology|March 25, 2008
Cigarette smoke, nicotine and cotinine protect against 6-hydroxydopamine-induced toxicity in SH-SY5Y cellsKaren Riveles, Luping Z Huang, Maryka Quik
Biochemical Pharmacology|July 9, 2013
Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout miceMaryka Quik, Carla Campos, Sharon R Grady
Pageof 8